CARDIOPLEGIC IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for CARDIOPLEGIC IN PLASTIC CONTAINER (CARDIOPLEGIC IN PLASTIC CONTAINER).

How it works

Cardioplegic solutions induce rapid diastolic cardiac arrest by elevating extracellular potassium concentration, which depolarizes the myocardial cell membrane and inactivates sodium channels, preventing action potential generation. Additional components (e.g., magnesium, calcium, buffers) preserve myocardial energy stores and minimize ischemic injury during cardiopulmonary bypass.

What the body does with it

Metabolism	Not metabolized; components are excreted renally or redistributed systemically after surgery.
Excretion	Renal elimination of potassium, magnesium, and sodium; dose-dependent; no biliary or fecal elimination of active components.
Half-life	Not applicable; components are endogenous electrolytes with rapid redistribution and renal excretion; clinical effect half-life is duration of cardiac arrest (typically 30–60 minutes).
Protein binding	Potassium: negligible (<5%); magnesium: ~30% bound to albumin; sodium: negligible.
Volume of Distribution	Potassium: 0.4–0.6 L/kg (total body water); magnesium: 0.3–0.5 L/kg; sodium: 0.6–0.7 L/kg.
Bioavailability	100% via intracoronary or aortic root administration (no first-pass metabolism).
Onset of Action	Immediately upon coronary perfusion; cardiac arrest within seconds of administration.
Duration of Action	Duration of cardiac arrest: 30–60 minutes depending on dose, temperature, and myocardial oxygen demand.

Classification & Brands

Dosing & administration

Administer as a single dose of 1 liter intravenously for induction of cardiac arrest during cardiopulmonary bypass. For maintenance, 300-500 mL every 20-30 minutes as needed to maintain asystole or electromechanical dissociation.

Dosage form	SOLUTION
Renal impairment	No dosage adjustment required; cardioplegic solution is used intraoperatively and effect is independent of renal function.
Liver impairment	No dosage adjustment required; metabolism is minimal and Child-Pugh score does not impact dosing.
Pediatric use	Weight-based dosing: 10-20 mL/kg as a single intravenous dose for induction of cardiac arrest. Maintenance: 5-10 mL/kg every 20-30 minutes as needed.
Geriatric use	No specific dose adjustment; use with caution due to potential for reduced cardiac reserve and increased sensitivity to electrolyte shifts.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for CARDIOPLEGIC IN PLASTIC CONTAINER (CARDIOPLEGIC IN PLASTIC CONTAINER).

Breastfeeding	No data on excretion in human milk. Systemic absorption after intracoronary administration is minimal. Risk to nursing infant is likely low. M/P ratio not known.
Teratogenic Risk	Cardioplegic solution is administered during cardiac surgery and contains high potassium concentrations. There are no adequate studies in pregnant women. Maternal cardiac arrest or hypoperfusion during cardiopulmonary bypass may cause fetal hypoxia and ischemia. Teratogenic risk cannot be excluded; use only if clearly needed.

Warnings & precautions

■ FDA Black Box Warning

This product contains potassium chloride; fatal hyperkalemia can occur if infused beyond cardiac chambers or if systemically absorbed. Use only for cardioplegia administration; do not administer intravenously.

Side Effect Profile

Serious Effects

Absolute Contraindications

Hyperkalemia, severe bradycardia, heart block (without pacemaker), hypocalcemia, or known hypersensitivity to any component.

Clinical Precautions

Precautions	Risk of hyperkalemia, hypokalemia, hypocalcemia, metabolic acidosis/alkalosis, and myocardial injury. Monitor serum electrolytes, ECG, and cardiac function continuously. Avoid extravasation or systemic absorption.
Food/Dietary	No dietary restrictions are required as this is administered intraoperatively. However, patients should follow the preoperative fasting guidelines provided by their surgical team.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

CARDIOPLEGIC IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for CARDIOPLEGIC IN PLASTIC CONTAINER (CARDIOPLEGIC IN PLASTIC CONTAINER).

How it works

What the body does with it

Metabolism	Not metabolized; components are excreted renally or redistributed systemically after surgery.
Excretion	Renal elimination of potassium, magnesium, and sodium; dose-dependent; no biliary or fecal elimination of active components.
Half-life	Not applicable; components are endogenous electrolytes with rapid redistribution and renal excretion; clinical effect half-life is duration of cardiac arrest (typically 30–60 minutes).
Protein binding	Potassium: negligible (<5%); magnesium: ~30% bound to albumin; sodium: negligible.
Volume of Distribution	Potassium: 0.4–0.6 L/kg (total body water); magnesium: 0.3–0.5 L/kg; sodium: 0.6–0.7 L/kg.
Bioavailability	100% via intracoronary or aortic root administration (no first-pass metabolism).
Onset of Action	Immediately upon coronary perfusion; cardiac arrest within seconds of administration.
Duration of Action	Duration of cardiac arrest: 30–60 minutes depending on dose, temperature, and myocardial oxygen demand.

Classification & Brands

Dosing & administration

Dosage form	SOLUTION
Renal impairment	No dosage adjustment required; cardioplegic solution is used intraoperatively and effect is independent of renal function.
Liver impairment	No dosage adjustment required; metabolism is minimal and Child-Pugh score does not impact dosing.
Pediatric use	Weight-based dosing: 10-20 mL/kg as a single intravenous dose for induction of cardiac arrest. Maintenance: 5-10 mL/kg every 20-30 minutes as needed.
Geriatric use	No specific dose adjustment; use with caution due to potential for reduced cardiac reserve and increased sensitivity to electrolyte shifts.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for CARDIOPLEGIC IN PLASTIC CONTAINER (CARDIOPLEGIC IN PLASTIC CONTAINER).

Breastfeeding	No data on excretion in human milk. Systemic absorption after intracoronary administration is minimal. Risk to nursing infant is likely low. M/P ratio not known.
Teratogenic Risk	Cardioplegic solution is administered during cardiac surgery and contains high potassium concentrations. There are no adequate studies in pregnant women. Maternal cardiac arrest or hypoperfusion during cardiopulmonary bypass may cause fetal hypoxia and ischemia. Teratogenic risk cannot be excluded; use only if clearly needed.

Warnings & precautions

■ FDA Black Box Warning

Side Effect Profile

Serious Effects

Absolute Contraindications

Hyperkalemia, severe bradycardia, heart block (without pacemaker), hypocalcemia, or known hypersensitivity to any component.

Clinical Precautions

Precautions	Risk of hyperkalemia, hypokalemia, hypocalcemia, metabolic acidosis/alkalosis, and myocardial injury. Monitor serum electrolytes, ECG, and cardiac function continuously. Avoid extravasation or systemic absorption.
Food/Dietary	No dietary restrictions are required as this is administered intraoperatively. However, patients should follow the preoperative fasting guidelines provided by their surgical team.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

Clinical Pearls	Cardioplegic solution is administered directly into the coronary arteries after aortic cross-clamping to induce rapid diastolic cardiac arrest. It must be kept cold (4-8°C) and may contain potassium, magnesium, or procaine. Do not use if precipitate or discoloration is present. Monitor serum potassium closely during and after cardiopulmonary bypass.
Patient Advice	This medication is given during heart surgery to temporarily stop your heart. · You may feel cold as the solution circulates through your heart. · Your heart function and electrolyte levels will be closely monitored during the procedure.